Alector, Inc. (ALEC)
ALEC Stock Price Chart
Explore Alector, Inc. interactive price chart. Choose custom timeframes to analyze ALEC price movements and trends.
ALEC Company Profile
Discover essential business fundamentals and corporate details for Alector, Inc. (ALEC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Feb 2019
Employees
175.00
Website
https://www.alector.comCEO
Arnon Rosenthal
Description
Alector, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering new treatments for neurodegenerative disorders. A key program in its pipeline is AL001, a humanized recombinant monoclonal antibody currently undergoing Phase III clinical trials. This investigational therapy targets a range of severe conditions, including frontotemporal dementia, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Additionally, AL101 is progressing through Phase I clinical trials for general neurodegenerative diseases, with a specific focus on Alzheimer's and Parkinson's. Further bolstering its Alzheimer's portfolio, Alector is evaluating AL002 in Phase II studies and AL003 in Phase I studies, both aimed at addressing Alzheimer's disease. In earlier-stage development, the company is also developing AL044, which targets the MS4A4A gene, identified as a risk factor for Alzheimer's disease. Alector has forged key partnerships to advance its mission. It collaborates with Adimab, LLC on antibody research and development. Furthermore, a significant strategic alliance with GlaxoSmithKline plc (GSK) focuses on the joint development and commercialization of monoclonal antibodies, specifically AL001 and AL101, for neurodegenerative conditions. Established in 2013, Alector's headquarters are located in South San Francisco, California.
ALEC Financial Timeline
Browse a chronological timeline of Alector, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.24, while revenue estimate is $1.43m.
Earnings released on 7 May 2026
EPS came in at -$0.21 surpassing the estimated -$0.35 by +40.00%, while revenue for the quarter reached $1.05m , missing expectations by -89.19%.
Earnings released on 25 Feb 2026
EPS came in at -$0.34 surpassing the estimated -$0.39 by +12.82%, while revenue for the quarter reached $6.24m , beating expectations by +218.63%.
Earnings released on 6 Nov 2025
EPS came in at -$0.34 surpassing the estimated -$0.42 by +19.05%, while revenue for the quarter reached $3.26m , beating expectations by +82.77%.
Earnings released on 7 Aug 2025
EPS came in at -$0.30 surpassing the estimated -$0.45 by +33.33%, while revenue for the quarter reached $7.87m , beating expectations by +180.73%.
Earnings released on 8 May 2025
EPS came in at -$0.41 surpassing the estimated -$0.44 by +6.82%, while revenue for the quarter reached $3.67m , missing expectations by -13.55%.
Earnings released on 26 Feb 2025
EPS came in at -$0.02 surpassing the estimated -$0.61 by +96.72%, while revenue for the quarter reached $54.24m , beating expectations by +165.82%.
Earnings released on 6 Nov 2024
EPS came in at -$0.43 surpassing the estimated -$0.53 by +18.87%, while revenue for the quarter reached $15.34m , missing expectations by -5.76%.
Earnings released on 7 Aug 2024
EPS came in at -$0.40 surpassing the estimated -$0.49 by +18.37%, while revenue for the quarter reached $15.08m , beating expectations by +4.74%.
Earnings released on 8 May 2024
EPS came in at -$0.38 surpassing the estimated -$0.48 by +20.83%, while revenue for the quarter reached $15.89m , beating expectations by +7.39%.
Earnings released on 27 Feb 2024
EPS came in at -$0.49 surpassing the estimated -$0.80 by +38.75%, while revenue for the quarter reached $15.19m , beating expectations by +57.57%.
Earnings released on 7 Nov 2023
EPS came in at -$0.53 surpassing the estimated -$0.65 by +18.46%, while revenue for the quarter reached $9.11m , missing expectations by -5.51%.
Earnings released on 3 Aug 2023
EPS came in at $0.02 surpassing the estimated -$0.82 by +102.44%, while revenue for the quarter reached $56.21m , beating expectations by +1.28k%.
Earnings released on 4 May 2023
EPS came in at -$0.55 surpassing the estimated -$0.75 by +26.67%, while revenue for the quarter reached $16.55m , beating expectations by +107.90%.
Earnings released on 28 Feb 2023
EPS came in at -$0.63 falling short of the estimated -$0.54 by -16.67%, while revenue for the quarter reached $14.44m , missing expectations by -52.10%.
Earnings released on 8 Nov 2022
EPS came in at -$0.56 falling short of the estimated -$0.43 by -30.23%, while revenue for the quarter reached $14.85m , missing expectations by -52.97%.
Earnings released on 4 Aug 2022
EPS came in at $0.12 surpassing the estimated -$0.47 by +125.53%, while revenue for the quarter reached $79.85m , beating expectations by +159.10%.
Earnings released on 5 May 2022
EPS came in at -$0.54 falling short of the estimated $0.37 by -245.95%, while revenue for the quarter reached $24.47m , missing expectations by -76.23%.
Earnings released on 24 Feb 2022
EPS came in at -$0.68 falling short of the estimated -$0.13 by -423.08%, while revenue for the quarter reached $13.99m , missing expectations by -83.31%.
Earnings released on 4 Nov 2021
EPS came in at $1.49 falling short of the estimated $2.09 by -28.71%, while revenue for the quarter reached $182.41m , beating expectations by +15.38%.
Earnings released on 3 Aug 2021
EPS came in at -$0.69 matching the estimated -$0.69, while revenue for the quarter reached $6.57m , meeting expectations.
ALEC Stock Performance
Access detailed ALEC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
